Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Ross W. Cheloha Clear advanced filters

  • Parathyroid hormone/parathyroid hormone-related peptide receptor (PTHR1) is a family B G-protein-coupled receptor and is involved in the regulation of skeletal development, bone turnover and mineral ion homeostasis. This Review discusses fundamental aspects of ligand-binding and signalling mechanisms at PTHR1, highlighting the relationship between ligand structural modification and variation in PTHR1 signalling responses. The action of these signalling mechanisms in disease states in which PTHR1 function has an important role are also discussed.

    • Ross W. Cheloha
    • Samuel H. Gellman
    • Thomas J. Gardella
    Reviews
    Nature Reviews Endocrinology
    Volume: 11, P: 712-724

  • Activated GPCRs signal through multiple pathways. Ligands that signal through a single pathway are highly valued. The authors demonstrate that tethering ligands to receptors via conjugation with binding nanobodies enables pathway-specific signaling.

    • Shivani Sachdev
    • Brendan A. Creemer
    • Ross W. Cheloha
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-15

  • Current parathyroid hormone (PTH) peptides have limited efficacy due to rapid clearance and short receptor binding. Here, the authors show that lipidation strategies can extend circulation time and receptor engagement, enhancing PTH peptide efficacy in vitro and in vivo

    • Jakob Höppner
    • Hiroshi Noda
    • Thomas J. Gardella
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-16

  • Antibodies conjugated to bioactive compounds can allow targeted delivery of therapeutics. Here the authors present a strategy for fusing nanobodies to suboptimal GPCR peptide ligands to potently and selectively activate receptors.

    • Ross W. Cheloha
    • Fabian A. Fischer
    • Hidde L. Ploegh
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-11